Pharma Focus Asia

Cambrex to Expand Its Edinburgh Screening Facility


Cambrex corporation announced plans to expand its facility in Edinburgh, Scotland, doubling the current footprint to 15,000 square feet.


Currently, Cambrex's Edinburgh facility provides solid form development services, including investigations such as salt, co-crystal and polymorph screening, as well as crystallisation process development and GMP analytical services.

The additional instruments and reactors for large-scale crystallisation studies and solid form screening capabilities will be the new features of the expanded facility.

Additionally, the company plans to install Ultra-Performance Liquid Chromatography (UPLC) and gas chromatography instruments, as well as additional Process Analytical Technology (PAT) tools.

The project is expected to be completed by the end of the year.


NameCambrex Corporation
LocationEdinburgh, Scotland
magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference